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Objective:Theroleforacellulardermalmatrixinimplant-basedbreastreconstruction—
providing coverage of the inferolateral border of the underlying prosthesis and allowing
control over the inframammary fold—has become increasingly popular. Although Al-
loDerm (LifeCell, Branchburg, NJ) is free of cellular components responsible for the
antigenic response, its processing does not guarantee sterility. In this study, we examine
the infectious complications in tissue expander/implant-based reconstruction with Allo-
Derm. Methods: A retrospective cohort analysis was completed on 321 implant-based
breast reconstructions over a 10-year period (1998–2008) at an academic institution. Of
these cases, 75 reconstructions used AlloDerm and 246 reconstructions did not. The
incidence of infections that required readmission for intravenous (IV) antibiotics and
explantation was determined. Prosthetic explants due to hematoma or patient dissat-
isfaction were excluded from analysis. Results: There were no differences in rates of
readmission for IV antibiotics (2.8% vs 5.3%; P = .291). The rate of explantation due
to infected ﬂuid collections and extrusion was higher in the AlloDerm group (8.0%,
n = 6) than that in the control group (1.6%, n = 4). This result was statistically signiﬁ-
cant (P = .013). Conclusion: In this study, the rates of IV antibiotic administration for
the treatment of cellulitis in implant-based breast reconstructions did not differ because
of the presence of AlloDerm; however, the rate of explantation was statistically higher in
reconstructionsusingAlloDerm.Thistechnique hasgreatpotentialinbreastreconstruc-
tion, especially for single-staged implant-based reconstruction, but careful counseling
of patients with regard to the higher risk of explantation is necessary.
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The AlloDerm sling has become an increasingly utilized technique in breast recon-
struction since it was ﬁrst reported by Breuing and Warren1 in 2005. It is used for single-
staged implant reconstructions, as well as for tissue expander/implant reconstructions.
AlloDerm is sutured to the inferolateral aspect of the pectoralis muscle and then anchored
to the chest wall in order to create an internal sling to support the prosthesis. This tech-
nique eliminates the need to elevate the serratus or superior aspect of the rectus muscle.
In addition, accurate placement and control of the inframammary fold is possible. The
main advantages that are reported for the use of the AlloDerm sling are decreased time of
reconstruction, improved aesthetic result, and decreased chest wall morbidity.1-5
AlloDerm is a human cadaver–derived acellular dermal matrix that has been decellu-
larized to remove all cells and antigenic components. The remaining matrix components
includecollagen,ﬁbronectin,elastin,hyaluronan,andproteoglycans,whichcanbeincorpo-
ratedbythesurroundingsofttissue.6 InitialreportsoftheAlloDermslingtechniquesuggest
that the complication rates are low and comparable with the traditional total muscle cover-
age of expanders and implants4,7-13; however, the proprietary process that is used to make
AlloDerm does not guarantee sterility. Because of this property, we investigated the inci-
dence of infectious complications in traditional implant-based versus AlloDerm/implant-
based breast reconstructions.
METHODS
All patients undergoing expander/implant-based primary breast reconstruction over a 10-
yearperiodfrom1998to2008atasingleacademicinstitutionwereexamined.Atotalof321
primary expander/implant-based reconstructions were identiﬁed, including 75 AlloDerm-
based reconstructions and 246 reconstructions without AlloDerm. Patients with primary
autologous reconstruction and subsequent expander/implant reconstruction were excluded.
A retrospective chart review was performed from online medical records to collect
information regarding patient demographics, procedure details, and surgical outcomes. In-
formation concerningpatientdemographics,procedure details,and surgicaloutcomeswere
obtained from online medical records and inpatient hospital records. Speciﬁc data included
patient comorbidities (diabetes mellitus, smoking status, hypertension, coronary heart dis-
ease, and obesity deﬁned by body mass index > 30), radiation treatment, and immediate
or delayed breast reconstruction. The 2 primary outcomes of the study are the incidence
of cellulitis requiring readmission for intravenous (IV) antibiotics and expander/implant
removal due to infected ﬂuid collection or extrusion. Cellulitis w a sd e ﬁ n e da se r y t h e m ai n
conjunction with a fever or an elevated white blood cell count. Prosthetic explantations due
to patient dissatisfaction were excluded from analysis. All surgeons in this study used 1
drain per breast at the time of reconstruction. There was no standard antibiotic or irrigation
protocol.
We assessed differences in patient characteristics by using the chi-square test, the
Fisher exact test, and the 2-sample t test. The Fisher exact test was used to compare
the primary outcomes (incidences of readmission for IV antibiotics and implant/expander
removalduetoinfection).Logisticregressionanalysiswasusedtocomparetherelationship
between radiation therapy (radiation or no radiation) and reconstruction timing (immediate
or delayed) with each of the primary outcomes. Differences in late complication outcomes
were analyzed by using the chi-square test and the Fisher exact test.
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This study was approved by the Institutional Review Board at Beth Israel Deaconess
Medical Center. Statistical analysis was performed using SPSS (Version 16, Chicago, Ill)
and SAS (Version 9.1, Cary, NC) statistical software package. Statistical signiﬁcance was
set at P <. 05.
RESULTS
There was no difference in the patient characteristics between the AlloDerm and traditional
implant-based reconstructions (Table 1). The mean age of the patients was 47.7 years
(range, 25–72), and there was no statistical signiﬁcant difference in the comorbidities in the
2 groups. There were no smokers or patients with coronary artery disease in the AlloDerm
group, but it was not signiﬁcant.
Analysis of the readmission rates for IV antibiotics to treat cellulitis after breast
reconstruction with an implant or expander revealed that there was no difference due to the
presenceofAlloDerm(Table2andFig1).Therateswere5.3%and2.8%forreconstructions
with and without AlloDerm, respectively (P = .291). In contrast, the explantation rate was
signiﬁcantly higher in the reconstructions using AlloDerm (Fig 2). Eight percent of the
AlloDerm group required removal of the prosthesis compared with 1.6% in the control
group (P = .013). In addition, neither radiation therapy (Table 3) nor the timing of the
reconstruction (Table 4) affected the rates of IV antibiotic treatment or explantation rates.
Chemotherapy was also not associated with an increased explantation rate. In the majority
of cases of explantation, the intraoperative cultures grew normal skin ﬂora.
Table 1. Patient characteristics
No AlloDerm AlloDerm Total P
Number, n
Primary reconstruction 246 75 321
Patients 163 41 204
Total operations 319 86 205
Age, y
Mean 47.7 49.1 47.9 .261∗
Range 25–72 25–72 25–72
Comorbidities
Smokers 13 (5.3%) 0 13 (4.0%) .044†
Coronary artery disease 5 (2.0%) 0 5 (1.6%) .591†
Hypertension 24 (9.8%) 5 (6.7%) 29 (9.0%) .497†
Diabetes 11 (4.5%) 3 (4.0%) 14 (4.4%) .999†
Obesity 22 (8.9%) 6 (8.0%) 28 (8.7%) 1.000†
Radiation therapy
No radiation 177 (72.0%) 47 (62.7%) 224 (69.8%) .125‡
Radiation 69 (28.0%) 28 (37.3%) 97 (30.2%)
Reconstruction timing
Immediate 192 (78.0%) 72 (96.0%) 264 (82.2%) .001†





Table 2. Infection rates and explantation
No AlloDerm AlloDerm
Expander Implant Total Expander Implant Total Overall total P








3 (1.5%) 1 (2.0%) 4 (1.6%) 1 (4.0%) 5 (10%) 6 (8.0%) 10 (3.1%) .013∗
∗Fisher exact test comparing No AlloDerm group to AlloDerm group.
Figure 1. Two weeks after single-stage, AlloDerm- and silicone implant–based
breast reconstruction following mastectomy. Cellulitis is visible at the inferior pole
of the left breast where AlloDerm was placed. This was treated with intravenous
antibiotics and resolved.
DISCUSSION
The use of AlloDerm for immediate implant-based and expander/implant reconstructions
has become popular in the past 4 years. The reported beneﬁts of this technique include
improved cosmetic appearance, decreased chest wall morbidity, and decreased time of
reconstruction. It was ﬁrst described by Brueing and Warren1 in 2005, who used this
technique for bilateral immediate breast reconstruction in 10 patients. In this initial study,
there were no complications such as infection, cellulitis, or implant exposure. Subsequent
studies reported similar results for immediate breast reconstruction using the AlloDerm
sling,withcomplicationratesrangingfrom0%to9%(Table5).2,3,5 Threeadditionalstudies
described the use of AlloDerm in staged breast reconstruction with tissue expanders.4,8,9
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One reported a 3.1% infection rate and a 1.5% explant rate,4 whereas the other had a
6.9% infection rate and a 1.7% explant rate.8 The most recent study reported an infection
rate of 3.4% that required explantation.9 A follow-up study from Breuing and Colwell7
reported results from 67 immediate and delayed reconstructions using either implants or
expanders/implants with AlloDerm. In this successive study, there was a 3% infection rate
and a 1.3% explant rate. It is difﬁcult to make any deﬁnitive conclusions on the basis
of these results since the sample sizes in each study are too small to generate adequate
power in a statistical analysis. In comparison, a large retrospective study of more than
1200 patients that examined acute complication rates during staged implant-based breast
reconstruction by Cordeiro and McCarthy14,15 reported an overall complication rate of
5.8% and an infection rate of 2.5%. The rate of premature explantation was 2.7%.
The traditional dictum in the setting of an infected prosthetic is removal followed
by delayed reconstruction because this provides the safest and most conservative course.
Salvage of an infected implant is associated with a high rate of late capsular contracture.
Courtiss et al16 had initially reported a series of implant infection rates for augmentation
mammaplasty at 1.7% (44/2659) and subcutaneous mastectomy at 7.0% (18/258). Suc-
cessful implant salvage was possible in 13 of 29 implants by passive wound drainage and
antibiotic therapy; however, 10 (77%) of those implants went on to develop ﬁrmness. Spear
et al,17 in a series of 26 infected or exposed implants, had previously examined strategies
for management and treatment. Although successful implant salvage was possible in 15 of
21 breast reconstruction cases, 3 required a subsequent capsulotomy and 1 required a latis-
simus dorsi ﬂap. However, these studies predate the use of AlloDerm, a biologic prosthetic,
in conjunction with a breast implant.
Figure 2. Six weeks after single-stage, AlloDerm- and silicone implant–based
breast reconstruction following mastectomy. Extrusion of the implant is seen, as
areas of AlloDerm were not incorporated and visible in the wound. Patient was
previously treated with intravenous antibiotics. This extrusion required removal of
the implant and a delayed reconstruction.
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Table 3. Infection rates and radiation therapy
No radiation (n = 224) Radiation (n = 97) Total (N = 321) P∗
Readmission for intravenous antibiotics, n (%)
No AlloDerm 6 1 7
AlloDerm 3 1 4
Total 9 (4.0%) 2 (2.1%) 11 (3.4%) .515
Explantation due to infection, seroma, or extrusion, n (%)
No AlloDerm 4 0 4
AlloDerm 3 3 6
Total 7 (3.1%) 3 (3.1%) 10 (3.1%) .999
∗Fisher exact test.
Table 4. Infection rates and immediate/ and delayed reconstruction
Immediate (n = 264) Delayed (n = 57) Total (N = 321) P∗
Readmission for intravenous antibiotics, n (%)
No AlloDerm 5 2 7
AlloDerm 4 0 4
Total 9 (3.4%) 2 (3.5%) 11 (3.4%) 1.000
Explantation due to infection, seroma, or extrusion, n (%)
No AlloDerm 3 1 4
AlloDerm 5 1 6
Total 8 (3.0%) 2 (3.5%) 10 (3.1%) .693
∗Fisher exact test.
Table 5. Literature review of readmission for intravenous antibi-
otics and explantation in AlloDerm-based breast reconstruction
Intravenous antibiotics Explantation
Breuing and Warren1 0/20 0/20
Salzberg3 0/76 0/76
Gamboa-Bobadilla2 1/13 1/13
Bindingnavele et al5 1/65 1/65
Breuing and Colwell7 1/67 2/67
Zienowicz and Karacaoglu4 0/30 0/30
Spear et al8 4/58 1/58
Namnoum9 1/29 1/29
In our study, the rate of inpatient readmission for IV antibiotics is 5.3% for AlloDerm-
based reconstructions. This rate is similar to the readmission rates for traditional implant-
based reconstructions at our institution, as well as to the previously published infection
rates for the use of the AlloDerm sling.1-5,7-15 In contrast, our explant rate is signiﬁ-
cantly higher in the AlloDerm-based reconstructions than that in the traditional method
(8.0% vs 1.6%, respectively) and is statistically signiﬁcant (P = .013; Table 2). It is also
higher than the currently reported premature explant rate for the AlloDerm sling method
(Table 5). We examined our data to determine whether previous radiation exposure or the
timing of the reconstruction (ie, immediate vs delayed) was a factor, but neither of them
proved to contribute to the explant rate (Tables 3 and 4).
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The most likely explanation for this difference is a learning curve. Since AlloDerm
is juxtaposed next to a prosthetic device, there is a lower threshold for explantation to
eliminate the infection, as the AlloDerm is not guaranteed to be sterile. A recent case report
examined possible salvage of an infected AlloDerm-based implant reconstruction with a
vacuum-assistedclosuredevice;however,morepatientsandlongerfollow-upisnecessary.18
As more experience is accrued with the use of AlloDerm in the setting of implant-based
breast reconstruction, implant salvage may be increasingly possible. However, the long-
term capsular contracture rate with AlloDerm is unknown, especially in the setting of an
infection. Recently, additional acellular dermal matrix products have been introduced into
the market for use in breast reconstruction, but our results apply only to AlloDerm since
the newer products were not available or used at our institution during the course of this
study.
Although we believe that AlloDerm can be a valuable tool as a method of providing
a single-stage, implant-based breast reconstruction, patients should be counseled that there
is currently a higher explant rate with AlloDerm sling method than that with the traditional
methods. As we gain more experience, this may improve.
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